select a format

Single User License
USD 250 INR 16023
Site License
USD 500 INR 32045
Corporate User License
USD 750 INR 48068

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Karo Pharma AB (KARO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Karo Pharma AB (KARO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH59487D
  • |
  • Pages: 37
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Karo Pharma AB (Karo Pharma), formerly Karo Bio AB, is a health care company that focuses on research and development of pharmaceutical products in the areas of cancer and inflammatory diseases. Its key research area involves nuclear receptors as target proteins for the development of new pharmaceuticals. Karo Pharma discovers drugs to target major diseases such as dyslipidemia; diabetes; autoimmune diseases such as rheumatoid arthritis, ulcerative colitis and multiple sclerosis; inflammation, multiple types of cancer, viral and bacterial infections. The company's projects are based on ROR gamma receptor and estrogen receptor. Its development pipeline also includes T268A Cold Spray which utilizes glucose oxidase enzyme in combination with glucose to fight against cold virus. Karo Pharma is headquartered in Huddinge, Stockholm, Sweden.

Karo Pharma AB (KARO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Karo Pharma AB, Medical Devices Deals, 2011 to YTD 2017 10

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Karo Pharma AB, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Karo Bio Enters Into Research Agreement With 4D Science 12

Karo Bio Extends Research Agreement With Pfizer For RORgamma Modulators 12

Karo Bio Enters Into Research Agreement With Pfizer For RORgamma Modulators 13

Karo Bio Extends Research Agreement With Zydus Cadila 14

Licensing Agreements 15

Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 15

Karo Bio Enters Into Licensing Agreement With Alkem 16

Equity Offering 17

Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 17

Karo Bio Raises USD29 Million in Rights Offering of Shares 19

Karo Bio Raises USD12 Million in Rights Offering of Shares 20

Karo Bio Raises USD1 Million in Private Placement of Shares 21

Karo Bio Completes Rights Offering of Shares for USD4.9 Million 21

Asset Transactions 22

Oasmia Pharma to Acquire Cancer Project KB9520 from Karo Pharma 22

Acquisition 23

Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 23

Karo Bio Acquires Tanomed for USD2.3 Million 24

Karo Pharma AB-Key Competitors 26

Key Employees 27

Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Oct 27, 2016: Karo Pharma: Interim Report January-September 2016 29

Jul 15, 2016: Karo Pharma: Interim Report January-June 2016 30

May 12, 2016: Karo Bio: Interim Report January-March 2016 31

Feb 12, 2016: Year-End Report 2015-Karo Bio 33

Other Significant Developments 36

May 04, 2017: Karo Pharma-Pfizer Collaboration reaches second milestone 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37

List of Figures

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Karo Pharma AB, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Karo Pharma AB, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Karo Pharma AB, Deals By Therapy Area, 2011 to YTD 2017 8

Karo Pharma AB, Medical Devices Deals, 2011 to YTD 2017 10

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Karo Bio Enters Into Research Agreement With 4D Science 12

Karo Bio Extends Research Agreement With Pfizer For RORgamma Modulators 12

Karo Bio Enters Into Research Agreement With Pfizer For RORgamma Modulators 13

Karo Bio Extends Research Agreement With Zydus Cadila 14

Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 15

Karo Bio Enters Into Licensing Agreement With Alkem 16

Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 17

Karo Bio Raises USD29 Million in Rights Offering of Shares 19

Karo Bio Raises USD12 Million in Rights Offering of Shares 20

Karo Bio Raises USD1 Million in Private Placement of Shares 21

Karo Bio Completes Rights Offering of Shares for USD4.9 Million 21

Oasmia Pharma to Acquire Cancer Project KB9520 from Karo Pharma 22

Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 23

Karo Bio Acquires Tanomed for USD2.3 Million 24

Karo Pharma AB, Key Competitors 26

Karo Pharma AB, Key Employees 27

Karo Pharma AB, Subsidiaries 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Karo Pharma AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com